NEW YORK – By the time the 18th annual BIO CEO & Investor Conference got under way on its second and last day, the issue of drug pricing vs. treatment value had already reared its head in nearly every panel. And, during a session convened Tuesday morning to tackle the topic head-on, industry experts said the debate is unlikely to fade away as it has in years past.